Research Scientist, Pathobiology Multiplexing and Emerging Technologies

---

Job description

Research Scientist, Pathobiology Multiplexing and Emerging Technologies
United States - California - Foster City

Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead's therapeutic areas of focus include HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions.

Making an impact on a global scale
Inclusion is one of the company's five core values. That's because we know that we are stronger and more innovative at Gilead when we are informed by a diverse set of backgrounds, experiences and points of view. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide.

When you join Gilead, you join our mission to change the world by enabling people to live healthier and more fulfilling lives. Come join a mission-driven bio-pharmaceutical organization that values inclusion and diversity, has a strong portfolio of products, and is constantly #CreatingPossible



The Pathobiology group is seeking a highly motivated individual with experience in multiplex immunofluorescence -based technologies to join the Multiplexing and Emerging Technology group. The successful candidate will work closely with internal research groups as well as external collaborators to identify and validate novel drug targets and their mechanism of action in areas of oncology, fibrosis, virology, and inflammation.

The successful candidate will have a background in biology or a related discipline and have experience in developing IHC, immunofluorescence and multiplex assays. Knowledge of, and experience with tissue based emerging technologies and analysis tools is desirable.

The successful candidate must be self-motivated and detail-oriented, exhibit strong organizational and communication skills with the ability to manage multiple priorities, and a proficient team-player.

Essential Duties and Job Functions:

• Work closely with investigators across Gilead to understand project requirements and execute tissue-based assays
  
• Develop and execute experimental protocols to answer biological questions using multiplexing technologies (e.g. Ultivue, Akoya) and imaging platforms (Zeiss AxioscanZ1, Akoya Polaris or similar).
  
• Lead evaluation of emerging tissue-based technologies through a combination of in-house efforts and the use of relevant CROs.
  
• Lead outsourced studies with CROs/ vendors, as applicable.
  

Knowledge, experience, and skills:

• PhD with 0-2 years of relevant work experience, or a master's degree with 6+ years of relevant experience.
  
• The successful candidate will have experience in multiplex IF assay development and show curiosity-driven engagement in scientific problems.
  
• Experience with multiple automated IHC platforms and imaging platforms is required.
  
• Strong verbal and written communication, teamwork and interpersonal skills are required.
  
• Experience with emerging tissue-based technologies is a plus.
  
• Experience in image analysis software (i.e.: Visiopharm, Halo, or similar) and data analysis programs (Excel, Spotfire, Prism, etc.) is preferred but not required.
  

For jobs in the United States:
As an equal opportunity employer, Gilead Sciences Inc. is committed to a diverse workforce. Employment decisions regarding recruitment and selection will be made without discrimination based on race, color, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression, veteran status, or other non-job related characteristics or other prohibited grounds specified in applicable federal, state and local laws. In order to ensure reasonable accommodation for individuals protected by Section 503 of the Rehabilitation Act of 1973, the Vietnam Era Veterans' Readjustment Act of 1974, and Title I of the Americans with Disabilities Act of 1990, applicants who require accommodation in the job application process may contact for assistance.

Following extensive monitoring, research, consideration of business implications and advice from internal and external experts, Gilead has made the decision to require all U.S. employees and contractors to receive the COVID-19 vaccines as a condition of employment. "Full vaccination" is defined as two weeks after both doses of a two-dose vaccine or two weeks since a single-dose vaccine has been administered. Anyone unable to be vaccinated, either because of a sincerely held religious belief or a medical condition or disability that prevents them from being vaccinated, can request a reasonable accommodation.

For more information about equal employment opportunity protections, please view the 'EEO is the Law' poster.

NOTICE: EMPLOYEE POLYGRAPH PROTECTION ACT
YOUR RIGHTS UNDER THE FAMILY AND MEDICAL LEAVE ACT

PAY TRANSPARENCY NONDISCRIMINATION PROVISION

Our environment respects individual differences and recognizes each employee as an integral member of our company. Our workforce reflects these values and celebrates the individuals who make up our growing team.

Gilead provides a work environment free of harassment and prohibited conduct. We promote and support individual differences and diversity of thoughts and opinion.

For Current Gilead Employees and Contractors:
Please log onto your Internal Career Site to apply for this job.

jeid-163c3dcd4dbbd7f71b5f2